tirzepatide sydney Weight loss drugs are rewriting the global business of how we eat There's a health safety alert
Description
Tirzepatide (Mounjaro ) is the first incretin-based glucose-lowering medication to be approved as an add-on to diet and exercise in adults with T2DM that targets both the glucose-dependent insulinotropic polypeptide receptor (GIP) and the glucagon-like peptide-1 (GLP-1) receptor
People living with type 1 diabetes have excessive cardiovascular mortality risk, which is partially attributed to traditional risk factors such as dyslipidemia, hypertension, hyperglycemia, and overweight/obesity (2)

Contact a licensed medical provider for eligibility screening

Do you gain weight back after stopping Mounjaro

To determine the impact of weight loss on improvements in insulin resistance, multiple linear regression analysis was conducted, taking into account potential confounding variables such as age, sex, metformin use, triglyceride levels, and glycated hemoglobin A1c

Together, these data indicate that low-dose tirzepatide effectively induced clinically meaningful weight loss in people with type 1 diabetes, yet the observed magnitude of effect surpassed outcomes reported in other populations
